SUBSEQUENT EVENTS

3 Months Ended

Mar. 31, 2012

SUBSEQUENT EVENTS [Abstract]

SUBSEQUENT EVENTS

NOTE 18 - SUBSEQUENT EVENT

On April 10, 2012, the Companyannounced that it received U.S. Food and Drug Administration (FDA) approval for its generic version of ViroPharma's Vancocin®. Vancocin® is indicated for the treatment of Clostridium difficile-associated diarrhea (CDAD), and is also used for the treatment of enterocolitis caused by Staphylococcus aureus including methicillin-resistant strains. According to IMS Health, Vancocin® 125mg and 250mg had combined sales of approximately $328 million in the U.S. for the twelve months ended December 31, 2011.